Internal Medicine, Endocrinology, Diabetes, & Metabolism · San Antonio, TX
NPI
1487636205
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
5107 Medical Drive
San Antonio, TX, 78229
Phone (210) 614-8612
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.7M
43,087 services
Medicare patients, 2024
1,243
Average age 73
Drug cost, 2024
$14.3M
12,006 prescriptions
Company payments, 2025
$184K
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Firas Akhrass was code 36415 (venipuncture blood collection), 3,536 times for 1,142 patients. In total Firas Akhrass billed 43,087 services in 97 codes, and Medicare paid $1.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-06-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 3,536 | 1,142 | $5.87 | $21K |
| 99214 Office E&M - Established | Office | 3,482 | 1,165 | $90.20 | $314K |
| 80053 Clinical Chemistry | Office | 2,915 | 1,109 | $10.29 | $30K |
| 83036 Blood Count | Office | 2,667 | 1,099 | $9.44 | $25K |
| 84443 Clinical Chemistry | Office | 2,400 | 1,048 | $16.36 | $39K |
| 80061 Clinical Chemistry | Office | 2,379 | 1,054 | $13.03 | $31K |
| 85025 Blood Count | Office | 2,206 | 1,027 | $7.58 | $17K |
| 84439 Clinical Chemistry | Office | 1,655 | 716 | $8.76 | $15K |
| 83970 Clinical Chemistry | Office | 1,373 | 782 | $40.18 | $55K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,369 | 833 | $13.00 | $18K |
| 82306 Clinical Chemistry | Office | 1,117 | 774 | $28.77 | $32K |
| 95251 Test - Miscellaneous | Office | 1,036 | 359 | $26.27 | $27K |
| 82728 Clinical Chemistry | Office | 1,014 | 622 | $13.24 | $13K |
| 82746 Clinical Chemistry | Office | 896 | 637 | $14.31 | $13K |
| 82607 Clinical Chemistry | Office | 874 | 619 | $14.70 | $13K |
By year: 2022 $734K for 40,071 services; 2023 $789K for 41,135 services; 2024 $1.7M for 43,087 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 3,536 | 1,142 | $5.87 | $21K |
| 80053 Clinical Chemistry | 2,915 | 1,109 | $10.29 | $30K |
| 83036 Blood Count | 2,667 | 1,099 | $9.44 | $25K |
| 84443 Clinical Chemistry | 2,400 | 1,048 | $16.36 | $39K |
| 80061 Clinical Chemistry | 2,379 | 1,054 | $13.03 | $31K |
| 85025 Blood Count | 2,206 | 1,027 | $7.58 | $17K |
| 84439 Clinical Chemistry | 1,655 | 716 | $8.76 | $15K |
| 83970 Clinical Chemistry | 1,373 | 782 | $40.18 | $55K |
| 82306 Clinical Chemistry | 1,117 | 774 | $28.77 | $32K |
| 82728 Clinical Chemistry | 1,014 | 622 | $13.24 | $13K |
Medicare prescription drug claims, 2024
In 2024, the drug Firas Akhrass prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,006 prescriptions and refills. In total Firas Akhrass wrote 12,006 Medicare prescriptions that cost $14.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,006 | 2,855 | 383 | $11K |
| Ozempic Semaglutide | 931 | 1,443 | 297 | $1.4M |
| Mounjaro Tirzepatide | 882 | 1,029 | 277 | $1.1M |
| Atorvastatin Calcium Generic | 607 | 1,758 | 279 | $6,147 |
| Afrezza Insulin Regular, Human | 555 | 598 | 186 | $1.4M |
| Farxiga Dapagliflozin Propanediol | 403 | 887 | 155 | $476K |
| Jardiance Empagliflozin | 319 | 779 | 134 | $442K |
| Metformin Hcl Er Metformin Hcl | 302 | 859 | 150 | $2,940 |
| Trulicity Dulaglutide | 298 | 433 | 104 | $410K |
| Synthroid Levothyroxine Sodium | 297 | 823 | 120 | $31K |
| Rosuvastatin Calcium Generic | 250 | 727 | 119 | $3,100 |
| Losartan Potassium Generic | 234 | 695 | 99 | $2,691 |
| Lisinopril Generic | 187 | 539 | 74 | $1,301 |
| Duloxetine Hcl Generic | 166 | 452 | 80 | $4,422 |
| Amlodipine Besylate Generic | 157 | 455 | 61 | $743 |
Brand drugs: 5,950 claims; generic drugs: 5,525 claims; opioid claims: 23.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Firas Akhrass $184K ($184K in general payments such as food, travel and fees) from 33 companies. The largest payer was Corcept Therapeutics with $52K.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 68 | $52K |
| Madrigal Pharmaceuticals MDGL | 66 | $47K |
| Novo Nordisk Inc NVO | 43 | $35K |
| Xeris Pharmaceuticals, Inc. | 34 | $20K |
| Lilly USA, LLC LLY | 47 | $20K |
| CeQur Corporation | 2 | $2,518 |
| Mannkind Corporation MNKD | 18 | $2,071 |
| Sequel Med Tech, LLC | 47 | $932 |
| Dexcom, Inc. DXCM | 17 | $560 |
| Ascensia Diabetes Care Us Inc. | 18 | $481 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.